Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In a mouse model of human ovarian cancer, the combination of tgDCC-E1A plus paclitaxel and cisplatin
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury